Closely-held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection...
Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...
Paul LaBarre PharmaJet named Paul LaBarre as VP of global business development to lead business development and commercialization strategies, replacing Melissa Malhame, who transitioned to a strategic advisory role for...
A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV) and...
Marian Wentworth Closely-held PharmaJet appointed Marian Wentworth, president and CEO of Management Sciences for Health since 2017, to its board. Management Sciences for Health is a non-profit organization that works...
Closely-held PharmaJet’s needle-free injection system will be used to deliver Diomics’ Diocheck SARS-CoV-2 visual immune response indicator. Diomics’ immune response indicator will be injected under the skin using...
Melissa Malhame Closely-held PharmaJet appointed Melissa Malhame as its VP of business development, where she will lead the company’s business development, sales, and marketing operations. “[Ms. Malhame’s] strategic...
Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...
Chris Cappello Closely-held PharmaJet appointed Chris Cappello as its president and CEO, replacing Ron Lowy, who was appointed as executive chairman. “In the 10 years that [Mr.Cappello] has worked for PharmaJet, he has...
By Len Zehr Closely-held PharmaJet’s needle-free injection devices have the potential to rapidly improve the delivery of vaccines in emerging markets as well as pharmaceuticals currently under development. “We are at...